Drug Profile
Lutetium-177 vipivotide tetraxetan - Advanced Accelerator Applications
Alternative Names: 177-Lutetium-PSMA-617 - Endocyte; 177Lu-EB-PSMA-617; 177Lu-PSMA; 177Lu-PSMA-617; 177LU-PSMA-617 - Endocyte; AAA617; Lu177 RLT; lutetium (177Lu) vipivotide tetraxetan; lutetium Lu 177 vipivotide tetraxetan - Advanced Accelerator Applications; Lutetium-177 PSMA 617; PluvictoLatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Endocyte; RadioMedix
- Developer Advanced Accelerator Applications; Australian and New Zealand Urogenital and Prostate Cancer Group; Australian Nuclear Science and Technology Organisation; Novartis
- Class Amides; Amines; Antineoplastics; Aza compounds; Carboxylic acids; Cyclic hydrocarbons; Cyclohexanes; Drug conjugates; Naphthalenes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 04 Apr 2024 Efficacy and adverse events data from a phase III PSMAfore trial in Prostate cancer released by Novartis
- 04 Apr 2024 Novartis plans a pre-taxane label expansion trial for Prostate cancer in second half of 2024
- 15 Mar 2024 Phase-III clinical trials in Prostate cancer (Second-line therapy or greater, In adults, In the elderly, Metastatic disease) in Israel (IV) (NCT05939414)